Drug repositioning: Re-investigating existing drugs for new therapeutic indications

Journal of Postgraduate Medicine

Volumn 57, Issue 2, 2011, Pages 153-160

  Padhy, B M ^a   Gupta, Y K ^b  

^a HAMDARD UNIVERSITY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Data mining; drug development; repositioning

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; AMFEBUTAMONE; AMPHOTERICIN; ATOMOXETINE; AURANOFIN; BIMATOPROST; BROMOCRIPTINE; CEFTRIAXONE; CLOFAZIMINE; COLCHICINE; DAPSONE; DISULFIRAM; DULOXETINE; EFLORNITHINE; GABAPENTIN; METHOTREXATE; MILNACIPRAN; MILTEFOSINE; MINOCYCLINE; MINOXIDIL; PLERIXAFOR; PROPRANOLOL; RALOXIFENE; RETINOIC ACID; ROPINIROLE; SILDENAFIL; THALIDOMIDE; UNINDEXED DRUG; ZIDOVUDINE;

ACNE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEART INFARCTION; AFRICAN TRYPANOSOMIASIS; ALCOHOLISM; AMYOTROPHIC LATERAL SCLEROSIS; ANGINA PECTORIS; ANGIOGENESIS; ANTHELMINTIC ACTIVITY; ATTENTION DEFICIT DISORDER; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BIOINFORMATICS; BREAST CANCER; CACHEXIA; CAENORHABDITIS ELEGANS; CELL ASSAY; CLINICAL TRIAL (TOPIC); COMPUTER PROGRAM; DATA BASE; DATA MINING; DEPRESSION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIABETES MELLITUS; DROSOPHILA MELANOGASTER; DRUG CONTROL; DRUG COST; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG QUALITY; DRUG REPOSITIONING; DRUG SAFETY; DRUG SCREENING; DRUG TREATMENT FAILURE; EPILEPSY; ERECTILE DYSFUNCTION; ERYTHEMA NODOSUM LEPROSUM; EUROPE; EX VIVO STUDY; EYE DISEASE; EYELASH; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; GENOMICS; GLAUCOMA; GOUT; GOVERNMENT; HEMATOPOIETIC STEM CELL; HIGH THROUGHPUT SCREENING; HIRSUTISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IN VIVO STUDY; INDIA; INFECTION; INFLAMMATION; INFLUENZA; LEISHMANIASIS; LEPROSY; LIBRARY; LIFESTYLE; LYMPHATIC FILARIASIS; MALARIA; MALE TYPE ALOPECIA; MELANOMA; MIGRAINE; MORBIDITY; MORNING SICKNESS; MORTALITY; MULTIPLE MYELOMA; MYCOSIS; NEOPLASM; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; OBESITY; OSTEOARTHRITIS; OSTEOPOROSIS; PAIN; PARKINSON DISEASE; PATENT; PEDIATRICS; PERICARDITIS; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PREGNANT WOMAN; PROMYELOCYTIC LEUKEMIA; PROTEOMICS; PSORIASIS; RECURRENT DISEASE; RESTLESS LEGS SYNDROME; REVIEW; RHEUMATOID ARTHRITIS; RISK; SMOKING CESSATION; STRESS INCONTINENCE; TREATMENT INDICATION; TROPICAL DISEASE; TUBERCULOSIS; UNITED STATES; VISCERAL LEISHMANIASIS; YAWS;

COMPUTATIONAL BIOLOGY; DATA MINING; DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS; INDIA;

EID: 80052218993     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.81870     Document Type: Review

References (77)

1. Wilson JF. Alterations in processes and priorities needed for new drug development. Ann Intern Med 2006;145:793-6. (Pubitemid 351650369)
2. Dueñas-González A, García-López P, Herrera LA, Medina-Franco JL, González-Fierro A, Candelaria M. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer 2008;7:82.
3. Ashburn TT, Thor KB. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83. (Pubitemid 39173508)
4. Kaitin KI. Deconstructing the drug development process: The new face of innovation. Clin Pharmacol Ther 2010;87:356-61.
5. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 2009;22:119-25.
6. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007;448:645-6. (Pubitemid 47236844)
7. Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm Med 2010;24:151-9.
8. O'Connor KA, Roth BL. Finding new tricks for old drugs: An efficient route for public-sector drug discovery. Nat Rev Drug Discov 2005;4:1005-14.
9. Prescribing information. SYMMETREL (Amantadine Hydrochloride, USP). Endo Pharmaceuticals Inc. USA. 2009. Available from: Http:// www.accessdata.fda.gov/ drugsatfda-docs/label/2009/016023s041, 018101s016lbl.pdf. [last accessed on 2011 Feb 17].
10. Mondal S, Bhattacharya P, Rahaman M, Ali N, Goswami RP. A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy. PLoS Negl Trop Dis 2010;4:e764.
11. Comprehensive Prescribing Information. BAYER SAFETY COATED ASPIRIN. Bayer Corporation, USA. Available from: Http://www. fda.gov/ohrms/dockets/ac/03/ briefing/4012B1-03-Appd%20 1-Professional%20Labeling.pdf [Last accessed on 2001 Feb 17].
12. Shaughnessy AF. Old drugs, new tricks. BMJ. 2011; 342:d741. doi: 10.1136/bmj.d741.
13. Prescribing information. STRATTERA (atomoxetine hydrochloride). Eli Lilly and Company, USA. 2010. Available from: Http://pi.lilly.com/ us/strattera-pi.pdf [Last accessed on 2001 Feb 17].
14. Prescribing information. CYCLOSET (bromocriptine mesylate). VeroScience LLC, USA. 2009 Available from: Http://www.accessdata. fda.gov/drugsatfda-docs/ label/2009/020866lbl.pdf. [Last accessed on 2001 Feb 17].
15. Prescribing information. NEURONTIN (gabapentin). Parke-Davis, Division of Pfizer Inc, USA. 2010. Available from: Http://www.pfizer. com/files/products/ uspi-neurontin.pdf [Last accessed on 2001 Feb 17].
16. Prescribing information. Methotrexate. Bedford Laboratories, USA. 2005. Available from: Http://www.bedfordlabs.com/products/inserts/ MTX-LYO-P00.pdf [Last accessed on 2001 Feb 17].
17. Bidabadi E, Mashouf M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatr Drugs 2010;12:269-75.
18. Avvisati G, Tallman MS. All-trans retinoic acid in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003;16:419-32.
19. Isotretinoin Patient Advice. Available from: Http://www.drugs.com/ ppa/isotretinoin-13-cis-retinoic-acid.html. [Last accessed on 2001 Feb 17].
20. Dusek P, Busková J, Ruzicka E, Majerová V, Srp A, Jech R, et al. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin Neuropharmacol. 2010;33:186-90.
21. Sannella AR, Casini A, Gabbiani C, Messori L, Bilia AR, Vincieri FF, et al. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications. FEBS Lett 2008;582:844-7.
22. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-7. (Pubitemid 40101145)
23. Zhang Y, Post-Martens K, Denkin S. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov Today 2006;11:21-7. (Pubitemid 43227848)
24. Gloeckner C, Garner AL, Mersha F, Oksov Y, Tricoche N, Eubanks LM, et al. Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proc Natl Acad Sci U S A 2010;107:3424-9.
25. Tiono AB, Dicko A, Ndububa DA, Agbenyega T, Pitmang S, Awobusuyi J, et al. Chlorproguanil-dapsone-artesunate versus chlorproguanildapsone: A randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2009;81:969-78.
26. Cvek B, Dvorak Z. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov Today 2008;13:716-22.
27. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-8. (Pubitemid 34498818)
28. Cole GM, Frautschy SA. Mechanisms of action of non-steroidal antiinflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol Disord Drug Targets 2010;9:140-8.
29. Bohlega S, Alsaadi T, Amir A, Hosny H, Karawagh AM, Moulin D, et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: Expert panel recommendations for the middle East region. J Int Med Res 2010;38:295-317.
30. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med 2007;356:2571-81. (Pubitemid 46961002)
31. Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): A patient-preference trial. Lancet Neurol 2009;8:334-44.
32. Smaldone C, Brugaletta S, Pazzano V, Liuzzo G. Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovasc Hematol Agents Med Chem 2009;7:279-94.
33. Zouboulis CC. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol 2009;1:188-92.
34. Tartaglia LA. Complementary new approaches enable repositioning of failed drug candidates. Expert Opin Investig Drugs 2006;15:1295-8. (Pubitemid 44615280)
35. Dudley JT, Schadt E, Sirota M, Butte AJ, Ashley E. Drug discovery in a multidimensional world: Systems, patterns, and networks. J Cardiovasc Transl Res 2010;3:438-47.
36. Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X, et al. Update of TTD: Therapeutic Target Database. Nucleic Acids Res 2010;38:D787-91.
37. Ma'ayan A, Jenkins SL, Goldfarb J, Iyengar R. Network analysis of FDA approved drugs and their targets. Mt Sinai J Med 2007;74:27-32. (Pubitemid 46957753)
38. Campbell SJ, Gaulton A, Marshall J, Bichko D, Martin S, Brouwer C, et al. Visualizing the drug target landscape. Drug Discov Today 2010;15:3-15.
39. Langer T, Hoffmann R, Bryant S, Lesur B. Hit finding: Towards 'smarter' approaches. Curr Opin Pharmacol 2009;9:589-93.
40. Poh A. Breathing new life into old drugs. Cambridge Healthtech Institute. Available from: Http://www.bio itworld.com/BioIT-Article. aspx?id=84348 [Last accessed on 2010 Sep 15].
41. Ha S, Seo YJ, Kwon MS, Chang BH, Han CK, Yoon JH. IDMap: Facilitating the detection of potential leads with therapeutic targets. Bioinformatics 2008;24:1413-5. (Pubitemid 351737154)
42. Chiang AP, Butte AJ. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin Pharmacol Ther 2009;86:507-10
43. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE. Drug discovery using chemical systems biology: Repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol 2009;5:e1000423.
44. Li YY, An J, Jones SJ. A large-scale computational approach to drug repositioning. Genome Inform 2006;17:239-47.
45. The Johns Hopkins Clinical Compound Screening Initiative. Available from: Http://www.jhccsi.org/background.html (last accessed on 2010 Sep 15].
46. Clinical trials based on the Johns Hopkins Clinical Compound Screening Initiative. The Johns Hopkins Clinical Compound Screening Initiative. Available from: Http://www.jhccsi.org/CT.html [Last accessed 2010 Sep 15].
47. The NIH Clinical Collection. Available from: Http://www. nihclinicalcollection.com [Last accessed on 2010 Sep 15].
48. CTSA Pharmaceutical Assets Portal. Available from: Http://www. ctsapharmaportal.org [Last accessed on 2010 Sep 15].
49. Giacomotto J, Ségalat L. High-throughput screening and small animal models, where are we? Br J Pharmacol 2010;160:204-16.
50. Merino A, Bronowska AK, Jackson DB, Cahill DJ. Drug profiling: Knowing where it hits. Drug Discov Today 2010;15:749-56.
51. Kasam V, Salzemann J, Botha M, Dacosta A, Degliesposti G, Isea R, et al. WISDOM-II: Screening against multiple targets implicated in malaria using computational grid infrastructures. Malar J 2009;8:88.
52. Biovista. Available from: Http://www. http://www.biovista.com [Last accessed on 2010 Sep 21].
53. BrainCells Inc. Available from: Http://www.braincellsinc.com [Last accessed on 2010 Sep 21].
54. Jenken Biosciences. Available from: Http://www.jenkenbio.com [Last accessed on 2010 Sep 21].
55. KineMed. Available from: Http://www.kinemed.com [Last accessed on 2010 Sep 21].
56. Melior Discovery Inc. Available from: Http://www.meliordiscovery. com [Last accessed on 2010 Sep 21].
57. Numedicus Ltd. Available from: Http://www.numedicus.co.uk [Last accessed on 2010 Sep 21].
58. Sosei Co. Ltd. Available from: Http://www.sosei.com [Last accessed on 2010 Sep 21].
59. Zalicus. Available from: Http://www.zalicus.com [Last accessed on 2010 Sep 21].
60. Sheikh K, Porter J, Kielmann K, Rangan S. Public-private partnerships for equity of access to care for tuberculosis and HIV/AIDS: Lessons from Pune, India.Trans R Soc Trop Med Hyg 2006;100:312-20. (Pubitemid 43174832)
61. Dash AP, Valecha N, Anvikar AR, Kumar A. Malaria in India: Challenges and opportunities. J Biosci 2008;33:583-92.
62. Narain JP, Dash AP, Parnell B, Bhattacharya SK, Barua S, Bhatia R, et al. Elimination of neglected tropical diseases in the South-East Asia Region of the World Health Organization. Bull World Health Organ 2010;88:206-10.
63. Evolving R&D for emerging markets. Nat Rev Drug Discov 2010;9:417-20.
64. Croft SL. Public-private partnership: From there to here. Trans R Soc Trop Med Hyg 2005;99:S9-14.
65. Gutteridge WE. TDR collaboration with the pharmaceutical industry. Trans R Soc Trop Med Hyg 2006;100:S21-5. (Pubitemid 44490166)
66. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46. (Pubitemid 35375612)
67. Open Source Drug Discovery. Available from: Http://www.osdd.net [Last accessed on 2010 Sep 25].
68. Computational Resources for Drug Discovery. Available from: Http:// crdd.osdd.net [Last accessed on 2010 Sep 25].
69. Sreelata M. Open source TB megaproject yields first fruits. Science and Development Network Science and Development Network 16 April 2010. Available from: Http://www.scidev.net/en/news/opensource- tb-megaproject-yields-first- fruits.html [Last accessed on 2010 Sep 25].
70. Golegaonkar SB, Bhonsle HS, Boppana R, Kulkarni MJ. Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin glycation assay. Eur J Mass Spectrom (Chichester, Eng) 2010;16:221-6.
71. Chatterjee P. TB drug may bring relief to diabetics. Indian Express. 23 May 2010. Available from: Http://www.indianexpress.com/news/ tb-drug-may-bring-relief-to-diabetics/622543 [Last accessed on 2010 Sep 25].
72. Drug Repositioning Summit. Cambridge Healthtech Institute. Available from: Http://www.healthtech.com/Conferences-Archive. aspx?id=93286 [Last accessed on 2010 Sep 25].
73. Rawal RK, Kumar A, Siddiqi MI, Katti SB. Molecular docking studies on 4-thiazolidinones as HIV-1 RT inhibitors. J Mol Model 2007;13:155-61. (Pubitemid 44823963)
74. Andres CJ, Bronson JJ, D'Andrea SV, Deshpande MS, Falk PJ, Grant- Young KA, et al. 4-Thiazolidinones: Novel inhibitors of the bacterial enzyme MurB. Bioorg Med Chem Lett 2000;10:715-7. (Pubitemid 30215869)
75. Connexios Life Sciences Pvt. Ltd. Available from: Http://www. connexios.com [Last accessed on 2010 Sep 25].
76. Jubilant Biosys Ltd. Available from: Http://www.jubilantbiosys.com [Last accessed on 2010 Sep 25].
77. GVKBIO. Available from: Http://www.gvkbio.com/index.php [Last accessed on 2010 Sep 25].